Coming SoonN-Acetyl Epitalon Amidate
$99.00A stabilized tetrapeptide that upregulates telomerase — the enzyme that maintains telomere length — and modulates circadian signaling through the pineal axis.
Derived from the Khavinson bioregulator lineage, with modifications (N-acetylation, C-amidation) that protect against enzymatic degradation.
Research interest centers on cellular aging and circadian re-entrainment.
Made in USA•Purity: 99% HPLC
- Telomerase ActivationUpregulates hTERT expression, the catalytic subunit of telomerase responsible for maintaining telomere length
- DNA BindingBinds ATTTC sequences in telomerase gene promoters, modulating transcription factor access
- Histone InteractionForms stable complexes with histone proteins at sites normally interacting with DNA
- Circadian ModulationInfluences clock gene expression through pineal gland signaling pathways
For in-vitro laboratory research use only. Not for human consumption.
Research Status:Pre-Clinical Studies
Extensive Russian preclinical data; no independent replication of human mortality claims; FDA Category 2 (cannot compound in US)
For laboratory research use only.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the active sequence of Epithalamin, a bovine pineal gland extract first studied in 1973. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epitalon has been researched for telomerase activation and circadian rhythm regulation.
The claims are extraordinary — telomere lengthening, mortality reduction, cancer prevention. The research body is extensive (775+ publications over 40 years). The critical problem: no independent laboratory has ever replicated Khavinson's findings.
N-Acetyl Epitalon Amidate is a stabilized form with protective modifications on both ends of the molecule, extending half-life in experimental systems.
Russian Studies
The research body comes almost entirely from Khavinson's group:
Animal Studies:
- In SHR mice, Epitalon increased maximum lifespan by 12-13% for the longest-lived 10% of animals (mean lifespan unaffected)
- Spontaneous leukemia development reduced 6-fold compared to controls
- Chromosome aberrations in bone marrow cells decreased by 17.1%
Human Studies (Claimed Findings):
| Study | Design | Claimed Finding |
|---|---|---|
| Kiev 15-year (n=79) | Epithalamin vs controls, 12-year follow-up | 28% lower mortality; 2× lower cardiovascular mortality |
| Combined therapy (n=266) | Thymalin + Epithalamin, 6-year treatment | 4.1-fold mortality reduction |
| Retinitis pigmentosa (n=162) | 5.0 mcg parabulbar injection, 10 days | 90% positive clinical effect |
Critical caveats: The Kiev studies were not blinded, randomization methodology is unclear, and no intention-to-treat analysis was reported. A 4.1-fold mortality reduction would be unprecedented for any intervention in medical history.
Independent Validation
A 2025 study from non-Russian researchers confirmed telomere elongation in cell lines — providing the first independent signal that the cellular mechanism exists. However, no independent replication exists for the human mortality claims.
The Epitalon research presents a genuine scientific paradox:
What supports interest:
- The mechanisms are biologically plausible
- The research body is extensive
- A 2025 independent study confirmed telomere elongation in cells
What requires skepticism:
- Every human clinical claim originates from a single research group
- Khavinson held 196 patents on these peptides (substantial conflict of interest)
- Commercial companies tied to his institute sell these products
- No conflict of interest disclosures appear in most publications
- The absence of independent replication after 40+ years is telling
The Alzheimer's Drug Discovery Foundation explicitly notes: "Every preclinical and clinical study discussed here has been conducted by Dr. Khavinson's group in Russia with no independent confirmation of their results."
As of September 2024, Epitalon is on the FDA's Category 2 Bulk Drug Substances list, meaning it "may present significant safety risks" and cannot be legally compounded by 503A pharmacies in the United States.
| Jurisdiction | Status |
|---|---|
| USA | Category 2 (cannot compound) |
| Russia | Epithalamin approved; Epitalon experimental |
| EU | Not recognized as medicinal product |
| Canada/Australia | Unapproved new substance |
In practice, only research-grade products are available in Western markets, labeled "not for human use" with associated purity and contamination risks.
From Russian clinical studies and research protocols:
- Standard protocol: 5-10 mg/day subcutaneous injection for 10-20 consecutive days
- Cycling: Repeated every 4-6 months (longevity focus) or annually (maintenance)
- Administration: Evening/bedtime preferred due to melatonin pathway effects
- Storage: Lyophilized powder stable 3 years frozen; reconstituted solution 6 weeks refrigerated
Reported side effects:
- Injection site reactions (most common)
- Fatigue/drowsiness
- Mild headaches
- Sleep pattern changes
Contraindications: Known hypersensitivity, pregnancy/breastfeeding (no safety data), active or suspected cancer (telomerase activation concern).
A 2025 systematic review in International Journal of Molecular Sciences states: "Information regarding critical issues about this peptide's safety is missing." The FDA cites immunogenicity as a significant risk.
Epitalon represents frontier science with compelling theoretical foundations but inadequate validation for clinical use:
- Cannot be legally compounded in the United States (FDA Category 2)
- Only research-grade products of variable quality are available
- Long-term safety data is described as "missing" even by proponents
- Extraordinary longevity claims rest entirely on unreplicated research from a single institute with substantial commercial interests
The prudent approach is to monitor for independent replication studies while recognizing that current evidence falls well short of established validation standards.
- Khavinson VKh et al. "AEDG Peptide Stimulates Gene Expression and Protein Synthesis during Neurogenesis." Molecules. 2020. PMC
- Anisimov VN et al. "Effect of Epitalon on biomarkers of aging, life span, and spontaneous tumor incidence." Biogerontology. 2003. PubMed
- Araj et al. "Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide." Int J Mol Sci. 2025. PMC
- Alzheimer's Drug Discovery Foundation. "Epithalamin/Epithalon Cognitive Vitality Report." 2015.
For laboratory research use only.
| Amino Acid Sequence | Ala-Glu-Asp-Gly |
|---|---|
| Single-Letter Code | AEDG |
| Molecular Formula | C14H22N4O9 |
| Molecular Weight | 390.35 g/mol |
| Amino Acid Count | 4 |
| CAS Number | 307297-39-8 |
| PubChem CID | 219042 |
| Origin | Synthetic tetrapeptide based on a naturally occurring epithalamin extract from the pineal gland, developed through Khavinson bioregulatory peptide research. N-acetyl amidate modification enhances stability. |
| Synonyms | Epithalon, Epithalone, AEDG peptide, Epitalamin, N-Acetyl Epitalon |
This product ships as lyophilized (freeze-dried) powder. After reconstitution, the solution requires different storage conditions than the powder.
Reconstituted Solution
Refrigerate2–8°C (36–46°F)Up to 30 daysDo not freeze. Use within 30 days of mixing.
Lyophilized Powder
Refrigerated2–8°C (36–46°F)Weeks to months
Frozen−20°C (−4°F) or belowMonths to years
All peptides are HPLC-purified to ≥99% purity. Each lot includes a Certificate of Analysis (COA) with exact purity percentage, mass spectrometry data, and amino acid analysis.
Lyophilized peptides should be stored at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles.
This product is sold strictly for in-vitro laboratory research purposes only. It is not intended for human consumption and is not a drug, cosmetic, or food product.
Currently we ship within the United States only. International shipping is not available at this time.